Navigation Links
ViroPharma Announces First Quarter 2013 Financial Results
Date:5/1/2013

EXTON, Pa., May 1, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced financial results for the first quarter of 2013. Net sales were $107 million for the first quarter ended March 31, 2013 as compared to $136 million in the comparative period of 2012.  The decline in net sales quarter over quarter was driven by the decrease in Vancocin revenues partially offset by commercial product growth for Cinryze. The first quarter 2013 U.S. Cinryze net sales which grew by 44 percent over the first quarter of 2012 to $97 million, including approximately $91 million of patient demand.  The balance represented additional inventory in the channel. 

"The early part of 2013 has seen great progress both in our commercial business as well as our development pipeline," stated Vincent Milano, ViroPharma's chief executive officer. "In addition to the virologic response data we will share during our conference call today from subjects enrolled into our two maribavir studies, we also expect results from several key programs for Cinryze in the coming quarters such as subcutaneous Cinryze administration, antibody-mediated rejection (AMR) in kidney transplant, new uses for C1 INH, as well as additional progress updates with maribavir."

Our GAAP net loss was $64 million in the first quarter of 2013 compared to net income of $20 million in the first quarter of 2012.  GAAP diluted net loss per share was $(0.98) for the first quarter of 2013 compared to GAAP diluted earnings per share of $0.26 for the same period in 2012. The loss for the quarter was driven by a $104 million non-cash impairment charge related to the Vancocin intangible asset due to rapid decline in market price of generic vancomycin. Also driving the quarter over quarter decrease was the loss of Vancocin revenues partially offset by the continued growth of Cinryze.

Non
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Participate in Two December Healthcare Investor Conferences
2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Spherix Announces Third Quarter Financial Results
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015 According to a new ... (Mesh/Tissue patch, Allograft, Xenograft, Suture Anchor, Interference Screws, Laparoscopic ... Breast augmentation) - Global Forecast to 2019", published by ... reach $14.7 Billion in 2019 from $10.3 Billion in ... to 2019. Browse 70 market data ...
(Date:3/6/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... Poyhonen , the Company,s President and Chief Executive Officer, ... Chief Financial Officer, will present an overview of Senomyx,s ... at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time) ...
(Date:3/5/2015)... NEW YORK , March 5, 2015  DuPont ... J.P. Morgan Aviation, Transportation and Industrials Conference held today ... Vice President Matthew L. Trerotola discussed strategy, ... Advanced Materials segments for DuPont.  Strengthening and growing the ... of the three areas of strategic priority for DuPont. ...
(Date:3/5/2015)... BioPlus Specialty Pharmacy (BioPlus) announces the hiring ... of Managed Care. In this role, Damm will build ... nation’s leading specialty pharmacies. , Damm, who is based ... pharmacy and biotech experience to his new position with ... and Pfizer. Prior to working in Healthcare Damm served ...
Breaking Biology Technology:Soft Tissue Repair Market worth $14.7 Billion in 2019 2Soft Tissue Repair Market worth $14.7 Billion in 2019 3Soft Tissue Repair Market worth $14.7 Billion in 2019 4SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE THE 27TH ANNUAL ROTH CONFERENCE 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 3DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2
... Feb. 12 Pharmacyclics, Inc.,(Nasdaq: PCYC ), ... clinical testing and several late stage preclinical programs,announced today ... new board,member. , Robert W. ... CEO of the,company after acting as interim CEO for ...
... Company Exceeds Sales and Earnings GuidanceCompany Reiterates 2009 Earnings ... 12 Cephalon, Inc . (Nasdaq: ... $1.943 billion, compared to sales of $1.727 billion for ... income per common share for the full year 2008 ...
... Inc., announced,today the appointment of John P. Walker as ... of Directors. Walker was most recently the,Chairman and ... in January 2009. , (Photo: ... Bio is focused on the development of induced pluripotent ...
Cached Biology Technology:Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 2Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 3Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 4Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 5Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 6Cephalon's New Product Launches Pace Record 2008 Sales 2Cephalon's New Product Launches Pace Record 2008 Sales 3Cephalon's New Product Launches Pace Record 2008 Sales 4Cephalon's New Product Launches Pace Record 2008 Sales 5Cephalon's New Product Launches Pace Record 2008 Sales 6Cephalon's New Product Launches Pace Record 2008 Sales 7Cephalon's New Product Launches Pace Record 2008 Sales 8Cephalon's New Product Launches Pace Record 2008 Sales 9Cephalon's New Product Launches Pace Record 2008 Sales 10Cephalon's New Product Launches Pace Record 2008 Sales 11Cephalon's New Product Launches Pace Record 2008 Sales 12Cephalon's New Product Launches Pace Record 2008 Sales 13Cephalon's New Product Launches Pace Record 2008 Sales 14Cephalon's New Product Launches Pace Record 2008 Sales 15Cephalon's New Product Launches Pace Record 2008 Sales 16Cephalon's New Product Launches Pace Record 2008 Sales 17Cephalon's New Product Launches Pace Record 2008 Sales 18Cephalon's New Product Launches Pace Record 2008 Sales 19Cephalon's New Product Launches Pace Record 2008 Sales 20Cephalon's New Product Launches Pace Record 2008 Sales 21iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer 2
(Date:2/18/2015)... SUNNYVALE, Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Conference, Boston, MA Tuesday, March 3, ... Institutional Investors Conference, Orlando, FL Wednesday, ... Accessing Live Webcasts To access the live webcasts for these ...
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... Aug. 5, 2013 - For a new study in ... how different concentrations of lipids affect growth performance in ... of lipids affect pigs. According to the researchers, ... absorption because swine genetics have improved over the years. ...
... University of Illinois scientists have evidence that lifelong exposure ... colon cancer by repressing a signal that leads to accelerated ... our study, we report a change in the expression of ... Chen, a U of I professor of food science and ...
... interact with one anotherand not just today. Scientists are studying ... the world in the ancient past and to identify ways ... to a new study published in the August 2 issue ... throughout Earth,s history, but the recent rate of global warming ...
Cached Biology News:Researchers re-evaluate swine nutrition 2Scientists learn how soy foods protect against colon cancer 2Looking to the past to predict the future of climate change 2